On September 25, 2025, BioLargo, Inc. announced the revocation of the technology license granted to Pooph Inc. and the termination of the license agreement. The decision followed Pooph’s failure to meet contractual obligations, including a payment of approximately $3.8 million owed to BioLargo. The revocation is effective immediately.
BioLargo’s notice states that Pooph is no longer permitted to market or sell any products that incorporate or are based on BioLargo’s patents, proprietary information, or disclosed know‑how. The company also requires Pooph to cease marketing and selling such products in its possession or through market portals such as Amazon. This action protects BioLargo’s intellectual property and prevents further revenue dilution.
The termination underscores the importance of contractual compliance for BioLargo’s partners and highlights the company’s willingness to enforce its IP rights. The $3.8 million payment default represents a significant financial loss that BioLargo seeks to recover. Investors should note that the revocation may impact future revenue projections and the company’s partnership strategy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.